<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17 PATIENT COUNSELING INFORMATION<BR>               <BR>                  "See FDA-Approved Patient Labeling (Patient Information)"<BR>                  To ensure the safe and effective use of DEXILANT, this information and instructions provided in the FDA-approved Patient Information Leaflet should be discussed with the patient. <BR>                  Inform the patient to watch for signs of an allergic reaction as these could be serious and may require that DEXILANT be discontinued.<BR>                  Advise the patient to immediately report and seek care for any cardiovascular or neurological symptoms including palpitations, dizziness, seizures, and tetany as these may be signs of hypomagnesemia [see Warnings and Precautions (5.3)].<BR>                  Advise the patient to tell their health care provider if they take atazanavir, tacrolimus, warfarin and drugs that are affected by gastric pH changes [see Drug Interactions (7)]<BR>                  <BR>                  Advise the patient to follow the dosing instructions in the Patient Information Leaflet and inform the patient that:<BR>                  <BR>                     DEXILANT is available as a delayed-release capsule.<BR>                     DEXILANT may be taken without regard to food.<BR>                     DEXILANT should be swallowed whole.<BR>                     Alternatively, DEXILANT capsules can be administered as follows: <BR>                           –Open capsule;<BR>                           –Sprinkle intact granules on one tablespoon of applesauce;<BR>                           –Swallow immediately. Granules should not be chewed.<BR>                           –Do not store for later use.<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>